Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: Characterization and risk factors

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Gallego, Miguel ^a,b,c   Pomares, Xavier ^a   Espasa, Mateu ^d   Castañer, Eva ^d   Solé, Mar ^e   Suárez, David ^b   Monsó, Eduard ^a,b,c   Montón, Concepción ^a  

^a HOSPITAL DE SABADELL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Institut Universitari Parc Tauli UAB   (Spain)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Bronchiectasis; Chronic colonization; Chronic obstructive pulmonary disease; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; GENOMIC DNA; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; TICARCILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AGED; ALCOHOL ABUSE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BODY MASS; BRONCHIECTASIS; BRONCHUS SECRETION; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC SIMILARITY; GENOTYPE; HOME OXYGEN THERAPY; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; LENGTH OF STAY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MORPHOTYPE; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; OUTPATIENT; PHENOTYPE; PHYLOGENETIC TREE; PRESCRIPTION; PREVALENCE; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SMOKING; SPUTUM CULTURE; VACCINATION; CASE CONTROL STUDY; CHRONIC DISEASE; COMPLICATION; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SPUTUM;

AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 84902921443     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-103     Document Type: Article

References (35)

1. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365. 10.1056/NEJMra0800353, 19038881.
2. Moreno C, Montón Y, Belmonte M, Gallego X, Pomares X, Real J. Causas de muerte en pacientes con EPOC grave. Factores pronósticos. Arch Bronconeumol 2009, 45:181-186.
3. Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009, 15:138-142. 10.1097/MCP.0b013e328321861a, 19532029.
4. Eller J, Ede A, Schaberg T, Niederman M, Mauch H, Lode H. Infective exacerbation of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 1998, 113:1542-1548. 10.1378/chest.113.6.1542, 9631791.
5. Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M, and study group of bacterial infection in COPD Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999, 116:40-46. 10.1378/chest.116.1.40, 10424501, and study group of bacterial infection in COPD.
6. Monsó E, Garcia-Aymerich J, Soler N, Farrero E, Felez MA, Antó JM, Torres A, EFRAM Investigators Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003, 131(1):799-804. 10.1017/S0950268803008872, 2870022, 12948381, EFRAM Investigators.
7. Lode H, Allewelt M, Balk S, De Roux A, Mauch H, Niederman M, Schmidt-Ioanas M. A prediction model for bacterial etiology in Acute Exacerbations of COPD. Infection 2007, 35:143-149. 10.1007/s15010-007-6078-z, 17565454.
8. García-Vidal C, Almagro P, Romaní V, Rodríguez-Carballeira M, Cuchi E, Canales L, Blasco D, Heredia JL, Garau J. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009, 34:1072-1078. 10.1183/09031936.00003309, 19386694.
9. Renom F, Yáñez A, Garau M, Rubí M, Centeno MJ, Gorriz MT, Medinas M, Ramis F, Soriano JB, Agustí A. Prognosis of COPD patients requiring frequent hospitalization: Role of airway infection. Respir Med 2010, 104:840-848. 10.1016/j.rmed.2009.12.010, 20106648.
10. Martínez-García MA, Soler-Cataluña JJ, Donat Y, Catalán P, Agramunt M, Ballestín J, Perpiñá-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137. 10.1378/chest.10-1758, 21546440.
11. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011, 17(Suppl. 6):E1-E59. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases.
12. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013, Available from: http://www.goldcopd.org/, From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
13. Rakhimova E, Wiehlmann L, Brauer AL, Sethi S, Murphy TF, Tã1-Aprmmler B. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 2009, 200:1928-1935. 10.1086/648404, 19919307.
14. Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martínez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008, 47:1526-1533. 10.1086/593186, 18990062.
15. Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung disease: cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 2010, 68:20-27. 10.1016/j.diagmicrobio.2010.04.008, 20727465.
16. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204. 10.7326/0003-4819-106-2-196, 3492164.
17. Celli BR, Cote CG, Marín JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
18. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251. 10.1016/0895-4356(94)90129-5, 7722560.
19. Pomares X, Monton C. Respiratory day hospital: what have we learned?. Med Clin (Barc) 2011, 136:454-455. 10.1016/j.medcli.2009.07.028, 19819498.
20. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005, 11(9):690-703. 10.1111/j.1469-0691.2005.01217.x, 16104983, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.
21. Patel IS, Vlahos I, Wilkinson TMA, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:400-407. 10.1164/rccm.200305-648OC, 15130905.
22. Lynch DA, Newell JD, Tschomper BA, Cink TM, Newman LS, Bethel R. Uncomplicated asthma in adults: comparison of CT appearances of the lungs in asthma and in healthy subjects. Radiology 1993, 188:829-833. 10.1148/radiology.188.3.8351357, 8351357.
23. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson J, Flower CDR. Chronic sputum production: correlation between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996, 51:914-918. 10.1136/thx.51.9.914, 472614, 8984702.
24. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975, 50(6):339-344.
25. Begoña Cacho J, Meseguer MA, Oliver A, Puig J. Diagnóstico Microbiológico de las Infecciones Bacterianas del tracto Respiratorio Inferior 2007, Madrid: SEIMC.
26. Cabello H, Torres A, Celis R, El-Ebiary M, Puig de la Bellacasa J, Xaubet A, González J, Agustí C, Soler N. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997, 10(5):1137-1144. 10.1183/09031936.97.10051137, 9163659.
27. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing 2004, M100-S114. Wayne: National Committee for Clinical Laboratory Standards, National Committee for Clinical Laboratory Standards.
28. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
29. Durmaz R, Otlu B, Koksal F, Hosoglu S, Ozturk R, Ersoy Y, Aktas E, Gursoy NC, Caliskan A. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 2009, 62:372-377.
30. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:853-860. 10.1164/rccm.200709-1413OC, 18202344.
31. Martínez-García MA, de la Rosa D, Soler-Cataluña JJ, Donat-Sanz Y, Catalán P, Agramunt M, Ballestín J, Valero I, Selma MJ, Roma A, Bertomeu M. Prognostic value of bronchiectasis in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:823-831. 10.1164/rccm.201208-1518OC, 23392438.
32. Almagro P, Salvadó M, García-Vidal C, Rodríguez-Carballeira M, Cuchi E, Torres J, Heredia J. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012, 84:36-43. 10.1159/000331224, 21996555.
33. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005, 55(6):921-927. 10.1093/jac/dki146, 15883175.
34. Hogardt M, Heesemann J. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr Top Microbiol Immunol 2013, 358:91-118.
35. Novosad SA, Barker AF. Chronic obstructive pulmonary disease and bronchiectasis. Curr Opin Pulm Med 2013, 19(2):133-139. 10.1097/MCP.0b013e32835d8312, 23287285.